Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
CoughUpper Respiratory Tract Infections
Interventions
DRUG

Flurbiprofen Oral Lozenge

This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.

DRUG

Difflam

This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.

DRUG

Flurbiprofen 8.75 MG

This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.

Trial Locations (1)

3010

University of Melbourne, Carlton

All Listed Sponsors
collaborator

Reckitt Benckiser LLC

INDUSTRY

lead

University of Melbourne

OTHER